-
公开(公告)号：AU2010294905A1
公开(公告)日：2012-04-05
申请号：AU2010294905
申请日：2010-08-26
Applicant: UCB PHARMA SA
Inventor： NOVOTNEY-BARRY ANNA-MARIE , HULHOVEN REGINALD , PARKER GERALD L , HOSKIN VIOLET A
Abstract: The invention relates to the treatment of autoimmune or inflammatory disorders with antibodies to CD22. In particular, the invention relates to the treatment of autoimmune or inflammatory disorders with epratuzumab with a new dosing regimen. More particularly, the invention relates to the treatment of SLE.
-
Patent Agency Ranking
公开(公告)号：EA026902B1
公开(公告)日：2017-05-31
申请号：EA201270433
申请日：2010-08-26
Applicant: UCB PHARMA SA
Inventor： NOVOTNEY-BARRY ANNA-MARIE , HULHOVEN REGINALD , PARKER GERALD L , HOSKIN VIOLET A
Abstract: Изобретениеотноситсяк способулечениякраснойволчанкиэпратузумабом, гдекурслечениясоставляет 12 недель, гдеэпратузумабвводятв фиксированнойдозе 600 мгодинразв неделю 4 разав кумулятивнойдозе 2400 мгэпратузумаба, споследующимповторениемкурсалечения. Эпратузумабвводятвнутривенно, подкожноиливнутримышечно.
-
公开(公告)号：AU2010294905B2
公开(公告)日：2016-09-22
申请号：AU2010294905
申请日：2010-08-26
Applicant: UCB PHARMA SA
Inventor： NOVOTNEY-BARRY ANNA-MARIE , HULHOVEN REGINALD , PARKER GERALD L , HOSKIN VIOLET A
Abstract: The invention relates to the treatment of autoimmune or inflammatory disorders with antibodies to CD22. In particular, the invention relates to the treatment of autoimmune or inflammatory disorders with epratuzumab with a new dosing regimen. More particularly, the invention relates to the treatment of SLE.
-
">
公开(公告)号：IN2196DEN2012A
公开(公告)日：2015-08-21
申请号：IN2196DEN2012
申请日：2012-03-13
Applicant: UCB PHARMA SA
Inventor： NOVOTNEY-BARRY ANNA-MARIE , HULHOVEN REGINALD , PARKER GERALD L , HOSKIN VIOLET A
IPC: C07K16/28
Abstract: The invention relates to the treatment of autoimmune or inflammatory disorders with antibodies to CD22. In particular, the invention relates to the treatment of autoimmune or inflammatory disorders with epratuzumab with a new dosing regimen. More particularly, the invention relates to the treatment of SLE.
-
公开(公告)号：MX2012002907A
公开(公告)日：2012-04-30
申请号：MX2012002907
申请日：2010-08-26
Applicant: UCB PHARMA SA
Inventor： NOVOTNEY-BARRY ANNA-MARIE , HULHOVEN REGINALD , PARKER GERALD L , HOSKIN VIOLET A
Abstract: La invención se relaciona con el tratamiento de trastornos autoinmunes o inflamatorios con anticuerpos para CD22. En particular, la invención se relaciona con el tratamiento de trastornos autoinmunes o inflamatorios con epratuzumab con un nuevo régimen de dosificación. Más particularmente, la invención se relaciona con el tratamiento de SLE.
-
公开(公告)号：CA2774244A1
公开(公告)日：2011-03-24
申请号：CA2774244
申请日：2010-08-26
Applicant: UCB PHARMA SA
Inventor： NOVOTNEY-BARRY ANNA-MARIE , HULHOVEN REGINALD , PARKER GERALD L , HOSKIN VIOLET A
Abstract: The invention relates to the treatment of autoimmune or inflammatory disorders with antibodies to CD22. In particular, the invention relates to the treatment of autoimmune or inflammatory disorders with epratuzumab with a new dosing regimen. More particularly, the invention relates to the treatment of SLE.
-
-
-
-
-
Search Results
6
records
(took 0.02 seconds)
